DeepMed Research

Shanghai Fudan University Huashan Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Tumor Vaccines for Solid Tumors

Recruiting

Conditions: Glioma
Solid Tumor

Interventions: Biological: tumor vaccine
Radiation: Radiotherapy
Drug: Chemotherapy
Procedure: Surgery

First Posted Date: 2023-10-26

Last Posted Date: 2023-10-26

Lead Sponsor: Huashan Hospital

Target Recruit Count: 340

Registration Number: NCT06102837

Locations: 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China

A Multicenter Phenotype-Genotype Analysis of DM1 Patients in China

Conditions: Myotonic Dystrophy 1

Interventions: Diagnostic Test: Brain MRI scan

First Posted Date: 2023-10-26

Last Posted Date: 2023-10-26

Lead Sponsor: Huashan Hospital

Target Recruit Count: 300

Registration Number: NCT06101940

Locations: 🇨🇳
Huashan Hospital, Shanghai, China

Hemorrhagic Brainstem Cavernous Malformations Treatment With Sirolimus: aSingle Centre, Randomized, Placebo-controlled Pilot Trial

Phase 2

Recruiting

Conditions: Cavernous Malformations
Intracerebral Hemorrhage
Brainstem Stroke

Interventions: Drug: Sirolimus
Drug: Starch flake

First Posted Date: 2023-10-19

Last Posted Date: 2024-12-20

Lead Sponsor: Huashan Hospital

Target Recruit Count: 75

Registration Number: NCT06091332

Locations: 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China

Study of Brain-Gut Function Reconstruction After Intersphincteric Resection for Ultra-Low Rectal Tumors

Not Applicable

Recruiting

Conditions: Rectal Neoplasms

Interventions: Device: Transcranial magnetic stimulation
Device: Sham Transcranial magnetic stimulationt

First Posted Date: 2023-10-13

Last Posted Date: 2023-10-13

Lead Sponsor: Huashan Hospital

Target Recruit Count: 57

Registration Number: NCT06082648

Locations: 🇨🇳
Huashan Hospital Affiliated to Fudan University, Shanghai, China

Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China

Recruiting

Conditions: Ischemic Stroke

Interventions: Drug: Tenecteplase
Drug: Alteplase

First Posted Date: 2023-10-12

Last Posted Date: 2023-10-12

Lead Sponsor: Huashan Hospital

Target Recruit Count: 1200

Registration Number: NCT06078995

Locations: 🇨🇳
Xin Chen, Shanghai, China

Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer

Interventions: Drug: sintilimab+metronomic PLOF

First Posted Date: 2023-09-26

Last Posted Date: 2024-12-30

Lead Sponsor: Huashan Hospital

Target Recruit Count: 50

Registration Number: NCT06054906

Locations: 🇨🇳
Huashan Hospital, Fudan University, Shanghai, China

MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

Recruiting

Conditions: Glioma

Interventions: Biological: DC vaccine

First Posted Date: 2023-09-21

Last Posted Date: 2023-09-21

Lead Sponsor: Huashan Hospital

Target Recruit Count: 360

Registration Number: NCT06043232

Locations: 🇨🇳
Huashan Hospital，Fudan University, Shanghai, China

Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients

Recruiting

Conditions: Tuberculosis
Latent Tuberculosis Infection

Interventions: Diagnostic Test: QuantiFERON-TB Gold (QFT) test

First Posted Date: 2023-09-13

Last Posted Date: 2025-04-01

Lead Sponsor: Huashan Hospital

Target Recruit Count: 31440

Registration Number: NCT06033807

Locations: 🇨🇳
Qianxi Center of Disease Control, Bijie, Guizhou, China
🇨🇳
Weining Center of Disease Control, Bijie, Guizhou, China
🇨🇳
Zhijin Center of Disease Control, Bijie, Guizhou, China

and more 41 locations

TB YOUTH - TB SYstemic Management Using One-month, Ultra-short TPT Regimen for ScHool Contacts

Phase 3

Recruiting

Conditions: Tuberculosis
Latent Tuberculosis

Interventions: Drug: isoniazid and rifapentine
Drug: Rifampin and Isoniazid

First Posted Date: 2023-09-01

Last Posted Date: 2025-04-01

Lead Sponsor: Huashan Hospital

Target Recruit Count: 2978

Registration Number: NCT06022146

Locations: 🇨🇳
People's Hospital of Fenggang, Zunyi, Guizhou, China
🇨🇳
People's Hospital of Honghuagang District, Zunyi, Guizhou, China
🇨🇳
People's Hospital of Meitan, Zunyi, Guizhou, China

and more 43 locations

Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer

Not Applicable

Recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Radiation: 68Ga/131I-SGMIB-ZT-199

First Posted Date: 2023-08-08

Last Posted Date: 2024-04-24

Lead Sponsor: Huashan Hospital

Target Recruit Count: 10

Registration Number: NCT05982626

Locations: 🇨🇳
Huashan Hospital, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy